Fox Chase Cancer Center Invests in Expanding Access to Lifesaving Radiopharmaceuticals for Cancer Patients
PHILADELPHIA (October 17, 2023) — As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells. The company’s technology platform is considered to be at the forefront of radiopharmaceutical research and designed to advance new therapies from clinical trials to commercialization. Fox Chase and Nucleus also have signed a Letter of Intent to potentially enable to a deeper collaboration, including partnership in developing a radiopharmaceutical manufacturing site and clinical trials involving radiopharmaceuticals.
VIEW STORY